Efficacy Summary

Understanding the Clinical Benefits of ZEJULA

ZEJULA demonstrated significant improvement in progression-free survival, regardless of BRCA status1

The National Comprehensive Cancer Network® (NCCN) guidelines recommend niraparib (ZEJULA) for maintenance therapy of patients with platinum-sensitive, recurrent ovarian cancer following partial or complete response to platinum-based chemotherapy.2

ZEJULA Provided More Time Without Disease Progression, Across Patient Subgroups, Regardless of BRCA Status1,3

This analysis is exploratory in nature; it does not control for type 1 error and is not powered to determine treatment effect in any subgroup.4

Similar magnitude of benefit within key demographic and prognostic subgroups3,4
Chart showing similar magnitude of benefit within key demographic and prognostic subgroups
BRCA, breast cancer susceptibility gene; CI, confidence interval; CR, complete response; gBRCAmut, germline BRCA mutated; HR, hazard ratio; HRD, homologous recombination deficiency; n/a, not applicable; non-gBRCAmut, not germline BRCA mutated; PR, partial response.

References: 1.  ZEJULA [package insert]. Waltham, MA: TESARO, Inc; 2017. 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer v4.2017. http://www.nccn.org/professionals/physician/gls/pdf/ovarian.pdf. Accessed December 10, 2017. 3. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164. 4. Data on file. TESARO, Inc.

Study design


See the clinical rigor behind the pivotal trial design for ZEJULA

View Trial Info

Efficacy data


See PFS in HRDpos and HRDneg patient subgroups

View Efficacy

Quality of life


Learn about the impact of ZEJULA on quality of life

See the Data

Pivotal trial


See the pivotal phase 3 trial publication

Access Publication